Related references
Note: Only part of the references are listed.Well-being beyond the bladder. How do we improve the overall health of patients with bladder cancer?
Matthew Mossanen et al.
BJU INTERNATIONAL (2018)
Quality Improvement Efforts in Radical Cystectomy: From Prehab to Rehab
Matthew Mossanen et al.
EUROPEAN UROLOGY (2018)
Addressing Financial Toxicity: The Role of the Urologist
Matthew Mossanen et al.
JOURNAL OF UROLOGY (2018)
Cost and cost-effectiveness studies in urologic oncology using large administrative databases
Ye Wang et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Associations of specific postoperative complications with costs after radical cystectomy
Matthew Mossanen et al.
BJU INTERNATIONAL (2018)
Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life
Marianne M. Casilla-Lennon et al.
JOURNAL OF UROLOGY (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
Guideline of guidelines: non-muscle-invasive bladder cancer
Solomon L. Woldu et al.
BJU INTERNATIONAL (2017)
Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes
Michael Rink et al.
EUROPEAN UROLOGY FOCUS (2015)
Knowledge of the Harms of Tobacco Use Among Patients With Bladder Cancer
Jeffrey C. Bassett et al.
CANCER (2014)
The burden of bladder cancer care: direct and indirect costs
Matthew Mossanen et al.
CURRENT OPINION IN UROLOGY (2014)
Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature
Joseph J. Crivelli et al.
EUROPEAN UROLOGY (2014)
The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease
Robert S. Svatek et al.
EUROPEAN UROLOGY (2014)
Comparison of Surveillance Strategies for Low-Risk Bladder Cancer Patients
Yuan Zhang et al.
MEDICAL DECISION MAKING (2013)
Impact of a Bladder Cancer Diagnosis on Smoking Behavior
Jeffrey C. Bassett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-Term Trends in Medicare Payments in the Last Year of Life
Gerald F. Riley et al.
HEALTH SERVICES RESEARCH (2010)
Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
Bas W. G. van Rhijn et al.
EUROPEAN UROLOGY (2009)
Economic aspects of bladder cancer: what are the benefits and costs?
K. D. Sievert et al.
WORLD JOURNAL OF UROLOGY (2009)
Optimal management of high-risk T1G3 bladder cancer: A decision analysis
Girish S. Kulkarni et al.
PLOS MEDICINE (2007)
Clinical model of lifetime cost of treating bladder cancer and associated complications
Elenir B. C. Avritscher et al.
UROLOGY (2006)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
The health economics of bladder cancer - A comprehensive review of the published literature
MF Botteman et al.
PHARMACOECONOMICS (2003)
Medicare beneficiaries' costs of care in the last year of life
C Hogan et al.
HEALTH AFFAIRS (2001)
Primary superficial bladder cancer risk groups according to progression, mortality and recurrence
F Millan-Rodriguez et al.
JOURNAL OF UROLOGY (2000)
Share Paper
